Target intelligence / Profile preview

Solute carrier family 39 member 5 (SLC39A5)

Target
SLC39A5
Molecular classification
Transporter, Metal ion transporter, Zinc transporter, Member of SLC39 (ZIP) family
01

Overview

Solute carrier family 39 member 5 (SLC39A5), commonly known as ZIP5, is a zinc transporter belonging to the ZIP family responsible for zinc influx across the basolateral membrane of polarized cells, particularly in intestinal enterocytes and pancreatic acinar cells[1][2][3][4]. It plays a central role in the homeostasis of zinc by mediating zinc excretion from the bloodstream into the intestine and regulating zinc levels in multiple tissues. SLC39A5 is essential in protecting the pancreas from zinc toxicity and facilitating normal zinc balance in the body—its expression is dynamically regulated according to zinc availability. Clinically, SLC39A5 mutations are linked to dominantly inherited high myopia (MYP24) and may have emerging roles in metabolic trait modulation, such as influencing type 2 diabetes risk via the regulation of serum zinc levels[2][4]. Loss of SLC39A5 function disrupts zinc distribution, leading to increased hepatic zinc and altered pancreatic zinc accumulation, especially under varying dietary conditions. No highly selective drugs are described for clinical use against this transporter, but genetic variants are under investigation as biomarkers for disease susceptibility and metabolic traits.

Other names
ZIP5Zinc transporter ZIP5ZRT/IRT-like protein 5ZIP-5LZT-Hs7MYP24
02

Mechanism of action

Modulation of zinc transport to alter intracellular and tissue zinc concentrations

03

Biological functions

Regulation of zinc homeostasisZinc excretion and absorptionMaintenance of intracellular zinc levelsPossible regulation of copper transportRegulation of glucose-stimulated insulin secretionModulation of extracellular matrix proteins in scleraMay influence BMP/TGF-beta signaling
04

Disease associations

High myopia (specifically Myopia 24, autosomal dominant)Zinc-induced acute pancreatitisPossible metabolic traits (e.g., type 2 diabetes risk modification)Eye development disordersOther (disturbances of zinc metabolism)
05

Safety considerations

Altered zinc homeostasis may impact liver and pancreatic functionLoss of function may increase susceptibility to zinc-induced pancreatitisPotential zinc or micronutrient imbalance if the transporter is targeted chronically
06

Biomarkers

Loss-of-function mutations in SLC39A5 for Myopia 24 (MYP24)Potential serum zinc levels (for risk of metabolic disease)

Beyond the preview

Go deeper on Solute carrier family 39 member 5 (SLC39A5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 39 member 5 (SLC39A5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call